1. Report Introduction

2. Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections Market Overview at a Glance
2.1. Market Share Distribution of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 2017
2.2. Market Share Distribution of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 2027

3. Disease Background and Overview: Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 7MM
4.3. Total Prevalent Patient Population of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in 7MM – By Countries

5. Epidemiology of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.1.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.1.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.1.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.1.6. Treatable Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.4.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.4.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.4.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.4.6. Treatable Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.5.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.5.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.5.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.5.6. Treatable Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.6.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.6.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.6.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.6.6. Treatable Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.7.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.7.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.7.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.7.6. Treatable Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.8.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.8.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.8.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.8.6. Treatable Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.9.3. Sub-Type Specific cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.9.4. Sex- Specific Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections *
5.9.5. Diagnosed Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
5.9.6. Treatable Cases of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections

6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Unmet Needs of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections

8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile

9. Pipeline Therapies – At a glance

10. Key Cross Competition

11. Emerging Therapies for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile

12. Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections : 7MM Market Analysis
12.1. 7MM Market Size of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
12.2. 7MM Percentage Share of drugs marketed for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections
12.3. 7MM Market Sales of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Products

13. Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States
13.1.2. Percentage Share of drugs marketed for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United States
13.1.3. Market Sales of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany
13.2.1.2. Percentage Share of drugs marketed for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Germany
13.2.1.3. Market Sales of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France
13.2.2.2. Percentage Share of drugs marketed for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in France
13.2.2.3. Market Sales of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy
13.2.3.2. Percentage Share of drugs marketed for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Italy
13.2.3.3. Market Sales of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain
13.2.4.2. Percentage Share of drugs marketed for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Spain
13.2.4.3. Market Sales of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in United Kingdom
13.2.5.3. Market Sales of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan
13.3.2. Percentage Share of drugs marketed for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections in Japan
13.3.3. Market Sales of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology
17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

*Indication Specific